This benefit is exemplified by the discoveries of loss-of-function variants that led to PCSK9 inhibitors3, the role of G6PD variants in diabetes complications4, and the association between APOL1 and chronic kidney disease5, all of which would not have been possible had it not been for research participants from populations of African descent6. Here, G6PD is linked to diabetes mellitus.